Article
Apaf1 nanoLuc biosensors identified lentinan as a potent synergizer of cisplatin in targeting hepatocellular carcinoma cells.
Biochemical and biophysical research communications - 5 Nov 2021
Wang Zhixin, Qu Kai, Zhou Lei, Ren Li, Ren Bin, Meng Fandi, Yu Wenhao, Wang Haijiu, Fan Haining
Abstract excerpt
Liver cancer is one of the most common malignancies that is difficult to treat due to late diagnosis and chemo-resistance. In the present study, we developed and validated a cell based split nanoLuc biosensor to monitor the Apaf1-Apaf1 interactions in response to apoptosis-inducing drugs such as cisplatin. We showed that the activity of split nanoLuc is reconstituted only in response to apoptotic inducer,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
